<DOC>
	<DOCNO>NCT02141477</DOCNO>
	<brief_summary>This clinical research study make 2 phase . The goal Phase 1 study test safety combination omacetaxine decitabine find best dose give future patient . The goal Phase 2 study learn dose help control AML and/or MDS . The safety continue study .</brief_summary>
	<brief_title>Omacetaxine Decitabine Acute Myelogenous Leukemia ( AML ) Myelodysplastic Syndrome ( MDS )</brief_title>
	<detailed_description>Study Groups : If find eligible take part study , assign study group base join study . Up 2 group 6 participant ( combine ) enrol Phase 1 portion study , 60 participant enrol Phase 2 . If enrolled Phase 1 , dose decitabine receive depend join study . If first group participant receive decitabine intolerable side effect , second group receive low dose . If enrolled Phase 2 , receive decitabine high dose tolerate Phase 1 . All participant receive dose level omacetaxine . Study Drug Administration : Each cycle 28 day . Omacetaxine give injection skin 2 time day , 12 hour apart ( +/- 3 hour ) Days 1-3 every cycle . Decitabine give vein 1 hour Days 1-5 every cycle . Study Visits : Every week ( +/- 2 day ) , blood ( 2-3 teaspoon ) collect routine test . If disease appear get good , blood drawn every 2-4 week still receive study drug , every 4 8 week long study . If live far clinic , blood urine collect clinic close home , result report study doctor . At begin every cycle , physical exam . At Week 3 ( +/- 7 day ) every 4 week ( +/- 7 day ) , may ( base result blood test ) bone marrow aspirate/biopsy collect check status disease cytogenetic testing . Length Study : You may continue take study drug 3 year long doctor think best interest . You longer able take study drug disease get bad , intolerable side effect occur , unable follow study direction . Your participation study follow-up visit . Follow Up : You follow-up visit every 3-6 month 5 year stop receive study drug . At visit , physical exam . If come clinic , may call study staff ask health . These call last 5-10 minute . This investigational study . Omacetaxine FDA approve commercially available treatment chronic myelogenous leukemia ( CML ) . Its use study investigational . Decitabine FDA approve commercially available treatment MDS . The study doctor explain study drug design work . Up 66 participant enrol study . All take part MD Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Homoharringtonine</mesh_term>
	<criteria>1 . Previously untreated AML ( &gt; /= 20 % blast ) AML M6 . Patients highrisk ( intermediate2 high IPSS &gt; /= 10 % blast ) MDS also eligible . Prior therapy hydroxyurea , biological target therapy ( e.g . flt3 inhibitor , kinase inhibitor , azacitidine ) , hematopoietic growth factor allow . No prior chemotherapy allow except single two day dose cytarabine ( 3 g/m2 ) emergency use also allow prior therapy . 2 . Age &gt; /= 70 year . 3 . ECOG performance status &lt; /= 2 . 4 . Adequate hepatic ( serum total bilirubin &lt; /= 1.5 x ULN , SGPT and/or SGOT &lt; /= 2.5 x ULN ) renal function ( creatinine &lt; /= 2.0 mg/dL ) . 5 . Patients must willing able review , understand , provide write consent start therapy . 6 . Men childbearing potential agree use contraception prior study entry duration participation . 1 . NYHA class III IV heart disease , active ischemia uncontrolled cardiac condition angina pectoris , clinically significant cardiac arrhythmia require therapy , uncontrolled hypertension ( blood pressure &gt; /= 160 systolic &gt; /= 110 diastolic responsive antihypertensive medication ) , uncontrolled diabetes mellitus , congestive heart failure . 2 . Myocardial infarction previous 12 week ( start treatment ) . 3 . Active uncontrolled disease/infection judge treat physician . 4 . Acute promyelocytic leukemia ( APL ) .</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Acute Myelogenous Leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>High Risk Myelodysplastic Syndrome</keyword>
	<keyword>MDS</keyword>
	<keyword>Omacetaxine</keyword>
	<keyword>Synribo</keyword>
	<keyword>Homoharringtonine</keyword>
	<keyword>Decitabine</keyword>
	<keyword>Dacogen</keyword>
</DOC>